Following a full submission
AWMSG advice |
||
| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED MAY 2008. Refer toTA323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (which replaced NICE TA142) for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | epoetin alfa (Eprex®) | |
| Formulation | solution for injection | |
| Reference number | 127 | |
| Indication | Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy) |
|
| Company | Janssen-Cilag Ltd | |
| BNF chapter | Nutrition & blood | |
| Submission type | Full | |
| Status | Superseded | |
| AWMSG meeting date | 02/12/2003 | |
| Ratification by Welsh Government | 01/03/2004 | |
| Date of issue | 30/04/2004 | |
| NICE guidance | ||